Searchable abstracts of presentations at key conferences in endocrinology

ea0009p93 | Endocrine tumours and neoplasia | BES2005

Associations and interactions between the co-regulatory protein SRC-1 and Ets-2 in breast cancer

McIlroy M , Myers E , Hill A , Young L

In breast cancer associations between p160 co-activator proteins and the development of resistance to endocrine treatment have been shown. We hypothesized that nuclear co-regulatory proteins may interact with non-steroid receptors. We investigated the effect of silencing the co-activator, SRC-1, on tumour cell growth in vitro. We also examined the MAPK activated transcription factors, Ets, as possible interaction proteins of the co-activator SRC-1 in human breast cancer. The e...

ea0007p117 | Endocrine tumours and neoplasia | BES2004

Managing prolactinomas: our experience at Preston

Banerjee M , Myers M , Vice P

Patients who have Sr. Prolactin level >3000 mU/l (n=24) were selected from the Biochemistry laboratory record & patients with confirmed diagnosis of prolactinoma (n=33) identified and / followed up at Endocrine Clinic between December 1999 and October 2001 were studied. The mean age of the patients were 45.03+ 14.09 years and 72% were women. Of the patients diagnosed to have prolactinoma, 16 had microprolactinoma. 16 had macroprolactinoma and 1 had stalk disconnection. ...

ea0091p13 | Poster Presentations | SFEEU2023

Phaeochromocytoma in pregnancy: not all hypertension is essential

Mankumare Mohitraje , Kejem Helmine , Myers Jenny , Mumby Clare

Case history: We report a case of a 36-year-old female. She was Para 1 and 10 years prior had a vaginal delivery of a normal sized infant after an uncomplicated pregnancy. She was subsequently diagnosed with hypertension managed with Ramipril-10mg. She booked in her second pregnancy at 12 weeks/gestation. Ramipril had been stopped at positive pregnancy test and booking blood pressure was 139/85. Labetalol was commenced and she was seen in the pregnancy hypertension clinic....

ea0017p12 | (1) | BSPED2008

Turner Syndrome in young adults: where are they now?

Myers A , McHugh J , McCrann A , Croasdell N , Roche E , Hoey H

Turner Syndrome is a chromosomal disorder, which affects approximately 1 in 2500 live female births. It is associated with significant morbidity throughout childhood, adolescence and into adulthood. Quality of life is reduced in a significant number of females with Turner Syndrome due to lack of focused health care particularly during the transition from paediatric to adult services. The purpose of this study was to assess the health status and well being of a cohort of young ...

ea0007oc26 | Endocrine tumours | BES2004

Mechanisms of HER2 resistance in endocrine tumours

Myers E , Hill A , McDermott E , O'Higgins N , Young L

Introduction: Regulation of HER2 through the transcription factor PEA3 is associated with tumour progression and resistance to endocrine treatment in human breast cancer. The mechanism of this resistance remains unclear. Activation of estrogen receptor co-activator proteins via the MAP-kinase pathway is thought to be central to tamoxifen insensitivity. We hypothesised that activation of HER2 by PEA3 may result in activation of co-activator proteins such as AIB1 (amplified-in-b...

ea0038p7 | Bone | SFEBES2015

Differential effects of parathyroid hormone on key regulators of osteoblast mineralisation

Houston Dean , Myers Katherine , MacRae Vicky , Millan Jose Luis , Staines Katherine , Farquharson Colin

Intermittent PTH therapy is currently the only anabolic therapy for osteoporosis. As the mineralisation of the extracellular matrix of bone is essential for normal function it is vital that the effects of PTH on key regulators of mineralisation are uncovered. Ablation of Alpl, Phospho1 or Smpd3 results in skeletal hypomineralisation and as such this study examined the effects of bovine (b)PTH 1–34 on their expression. MC3T3 (clone-14) osteoblast-like cells display tempora...

ea0023p29 | (1) | BSPED2009

46, XY DSD: A case of clinical and biochemical conflict

Myers Aisling , Hughes Ieuan , Achermann John , Lynch Sally Ann , Roche Edna , Hoey Hilary

Introduction: We describe a case of 17- beta hydroxysteroid dehyrogenase Type III (17-βHSD3) deficiency in a girl from the travelling community. This case demonstrates how the clinical picture may not correlate with the biochemical results.Case: A 4.7 year old girl presented for elective hernia repair. Intraoperatively, what was felt to be a testis was palpated. Investigations revealed a 46, XY karyotype. Pelvic ultrasound demonstrated absence of mu...

ea0014p348 | (1) | ECE2007

Removal of tick box for TFT in pathology request forms reduces TFT performed during acute medical admission

Piya Milan , Belbase Biparna , Thapa Meenakshi , Koppada Anu , Myers Martin , Baxter Susan , Rajbhandari Satyan

Joint UK guideline (2006) recommends that routine testing of thyroid function (TFT) in patients admitted acutely to hospital is not warranted unless specific clinical indications exist. Despite this, TFT is frequently requested during acute medical admission. In our previous audit in 2002, during a 1 month period from 18th September, 458 subjects were admitted to medical assessment unit (MAU) and 183 (40%) were offered TFT. 39 (29%) results were beyond the laboratory reference...

ea0013p296 | Thyroid | SFEBES2007

Removal of tick box for TFT in pathology request forms reduces TFT performed during acute medical admission

Piya Milan , Belbase Biparna , Karki-Thapa Meenakshi , Baxter Susan , Myers M , Koppada A , Rajbhandari Satyan Man

Joint UK guideline (2006) recommends that routine testing of thyroid function (TFT) in patients admitted acutely to hospital is not warranted unless specific clinical indications exist. Despite this, TFT is frequently requested during acute medical admission. In our previous audit in 2002, during a 1 month period from 18th September, 458 subjects were admitted to medical assessment unit (MAU) and 183 (40%) were offered TFT. 39 (29%) results were beyond the laboratory reference...

ea0005p143 | Endocrine Tumours and Neoplasia | BES2003

Transcriptional regulation by PEA3 in human breast cancer

Myers E , Buggy Y , Hill A , Duffy M , O'Higgins N , Young L

Her-2/neu over-expression is associated with elevated tumorigenicity and enhanced metastatic potential. Recently a DNA motif containing the consensus binding site of PEA3, a member of the ets transcription factor family has been identified on the Her-2/neu promoter. Activation of the PEA3 response element has been proposed to be involved in the transcriptional squelching of Her-2/neu.Methods: Using RT-PCR we have determined PEA3 mRNA expression in human breast tissue and l...